Estrella Immunopharma (ESLA) Stock Price, News & Analysis

Company Overview

Estrella Immunopharma, Inc. (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company’s work centers on genetically engineered T-cell therapies designed to recognize and destroy target cells.

Estrella’s lead program is EB103, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of certain B-cell malignancies. The company has described EB103 as being based on its ARTEMIS platform, which is intended to support targeted immune-cell activity while addressing some limitations associated with conventional CAR-T therapies.

Estrella became a publicly traded company through a business combination with TradeUP Global Corporation. Its publicly available materials primarily describe a research and clinical-development operation; specific commercial products, geographic markets, and broader leadership details should be confirmed through the company’s latest regulatory filings and corporate disclosures.

Key Stats

• Today's Range: $0.62 to $0.79
• 50-Day Range: $0.31 to $0.99
• 52-Week Range: $0.24 to $3.15
• Volume: 165,669 shs
• Average Volume: 5.62 million shs
• Market Capitalization: $27.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Hold

Estrella Immunopharma Stock Analysis - MarketRank™

Estrella Immunopharma scored higher than 40% of companies evaluated by MarketBeat, and ranked 693rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Estrella Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Estrella Immunopharma has a consensus price target of $8.00, representing about 1,151.4% upside from its current price of $0.64.

Amount of Analyst Coverage

Estrella Immunopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Estrella Immunopharma are expected to decrease in the coming year, from ($0.25) to ($0.32) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.46% of the float of Estrella Immunopharma has been sold short.

Short Interest Ratio / Days to Cover

Estrella Immunopharma has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Estrella Immunopharma has recently increased by 180.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Estrella Immunopharma does not currently pay a dividend.

Dividend Growth

Estrella Immunopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.36

News Sentiment

Estrella Immunopharma has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Estrella Immunopharma this week, compared to 1 article on an average week.

Search Interest

2 people have searched for ESLA on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Estrella Immunopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Estrella Immunopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.80% of the stock of Estrella Immunopharma is held by insiders.

Percentage Held by Institutions

0.35% of the stock of Estrella Immunopharma is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/30/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ESLA
• CIK: 1844417
• Web: www.estrellabio.com
• Phone: 510-318-9098
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Estrella Immunopharma: $8.00
• High Price Target: $8.00
• Low Price Target: $8.00
• Potential Upside/Downside: +1,151.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -328.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.20
• Quick Ratio: 0.20

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.27) per share
• Price / Book: -2.37

Miscellaneous

• Outstanding Shares: 43,500,000
• Free Float: 40,975,000
• Market Cap: $27.81 million
• Optionable: Not Optionable
• Beta: 0.93